Welcome to LookChem.com Sign In|Join Free

CAS

  • or
Ethyl (tetrahydro-4H-pyran-4-ylidene)acetate is a chemical compound known for its distinctive fruity, floral odor with a sweet and slightly woody undertone. It is widely recognized for its ability to enhance the sensory experience of consumers in various products.

130312-00-4 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 130312-00-4 Structure
  • Basic information

    1. Product Name: Ethyl (tetrahydro-4H-pyran-4-ylidene)acetate
    2. Synonyms: 4-(2-Ethoxycarbonylmethylene)tetrahydropyran;Ethyl (tetrahydro-4H-pyran-4-ylidene)acetate;Ethyl (tetrahydro-4H-pyran-4-ylidene)acetate 97%;Ethyl (tetrahydropyran-4-ylidene)acetate;ethyl 2-(tetrahydropyran-4-ylidene)acetate;Ethyl 2-(dihydro-2H-pyran-4(3H)-ylidene)acetate;4-(2-Ethoxy-2-oxoethylidene)tetrahydro-2H-pyran, (Tetrahydro-4H-pyran-4-ylidene)acetic acid ethyl ester;ethyl 2-(oxan-4-ylidene)acetate
    3. CAS NO:130312-00-4
    4. Molecular Formula: C9H14O3
    5. Molecular Weight: 170.20566
    6. EINECS: N/A
    7. Product Categories: blocks;Carboxes;Heterocycles
    8. Mol File: 130312-00-4.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: 248.978 °C at 760 mmHg
    3. Flash Point: 97.786 °C
    4. Appearance: /
    5. Density: 1.125 g/cm3
    6. Vapor Pressure: 0.024mmHg at 25°C
    7. Refractive Index: 1.528
    8. Storage Temp.: Sealed in dry,Room Temperature
    9. Solubility: N/A
    10. CAS DataBase Reference: Ethyl (tetrahydro-4H-pyran-4-ylidene)acetate(CAS DataBase Reference)
    11. NIST Chemistry Reference: Ethyl (tetrahydro-4H-pyran-4-ylidene)acetate(130312-00-4)
    12. EPA Substance Registry System: Ethyl (tetrahydro-4H-pyran-4-ylidene)acetate(130312-00-4)
  • Safety Data

    1. Hazard Codes: Xi
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 130312-00-4(Hazardous Substances Data)

130312-00-4 Usage

Uses

Used in Fragrance Industry:
Ethyl (tetrahydro-4H-pyran-4-ylidene)acetate is used as a fragrance ingredient for its pleasant aroma, contributing to the scent profiles of perfumes, soaps, and other scented products.
Used in Food and Beverage Industry:
Ethyl (tetrahydro-4H-pyran-4-ylidene)acetate is used as a flavoring agent to add a fruity and floral taste to food and beverages, enhancing their overall flavor profile and appeal to consumers.
Used in Cosmetic Industry:
Ethyl (tetrahydro-4H-pyran-4-ylidene)acetate is utilized in the cosmetic industry to improve the scent of products, making them more attractive to users and enhancing their sensory experience.

Check Digit Verification of cas no

The CAS Registry Mumber 130312-00-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,0,3,1 and 2 respectively; the second part has 2 digits, 0 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 130312-00:
(8*1)+(7*3)+(6*0)+(5*3)+(4*1)+(3*2)+(2*0)+(1*0)=54
54 % 10 = 4
So 130312-00-4 is a valid CAS Registry Number.
InChI:InChI=1/C9H14O3/c1-2-12-9(10)7-8-3-5-11-6-4-8/h7H,2-6H2,1H3

130312-00-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 11, 2017

Revision Date: Aug 11, 2017

1.Identification

1.1 GHS Product identifier

Product name ethyl 2-(oxan-4-ylidene)acetate

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:130312-00-4 SDS

130312-00-4Relevant articles and documents

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF HPK1

-

Page/Page column 199, (2021/01/29)

This disclosure relates to heterocyclics as inhibitors of HPK1, in particular relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising said compound that useful for treatment of HPK1 mediated diseases and conditions such as cancer. (I)

NEW MACROCYCLIC LRRK2 KINASE INHIBITORS

-

Page/Page column 258-259, (2021/11/13)

Compounds of formula (I): wherein R, X1, X2, X3, Z1, Z2, Z3, A and Ra are as defined in the description. Medicaments.

Synthesis of All-Carbon Quaternary Centers by Palladium-Catalyzed Olefin Dicarbofunctionalization

Koy, Maximilian,Bellotti, Peter,Katzenburg, Felix,Daniliuc, Constantin G.,Glorius, Frank

supporting information, p. 2375 - 2379 (2020/01/24)

The redox-neutral dicarbofunctionalization of tri- and tetrasubstituted olefins to form a variety of (hetero)cyclic compounds under photoinduced palladium catalysis is described. This cascade reaction process was used to couple styrenes or acryl amides with a broad range of highly decorated olefins tethered to aryl or alkyl bromides (>50 examples). This procedure enables one or two contiguous all-carbon quaternary centers to be formed in a single step. The products could be readily diversified and applied in the synthesis of a bioactive oxindole analogue.

Visible-Light-Promoted Intramolecular α-Allylation of Aldehydes in the Absence of Sacrificial Hydrogen Acceptors

Liu, Feng,Liu, Jia-Li,tu, Jia-Lin

supporting information, p. 7369 - 7372 (2020/10/05)

We report herein an unprecedented protocol for radical cyclization of aldehydes with pendant alkenes via synergistic photoredox, cobaloxime, and amine catalysis. The transformation was achieved in the absence of external oxidants, providing a variety of 5-, 6-, and 7-membered ring products with alkene transposition in satisfactory yields. The reaction exhibits wide functional group compatibility and occurs under mild conditions with extrusion of H2.

ROR-GAMMA INHIBITORS

-

Page/Page column 245, (2019/04/26)

The present invention relates to compounds of formula I and pharmaceutical compositions comprising compounds of formula I. Compounds of Formula I are useful in treatment of inflammatory, metabolic or autoimmune diseases which are mediated by RORy.

Providing a New Aniline Bioisostere through the Photochemical Production of 1-Aminonorbornanes

Staveness, Daryl,Sodano, Taylor M.,Li, Kangjun,Burnham, Elizabeth A.,Jackson, Klarissa D.,Stephenson, Corey R.J.

supporting information, p. 215 - 226 (2019/01/21)

Recent years have witnessed an increasing focus on saturated substructures within drug development as a result of the pharmacokinetic and toxicological benefits correlated with higher saturation content. However, the synthetic challenges presented by densely functionalized saturated architectures generally prohibit their evaluation. The abundance of anilines within high-throughput screening libraries is demonstrative of these competing needs. Anilines are prone to adverse metabolic processing, commonly necessitating re-engineering of a given drug lead to ameliorate CYP450 inhibition and/or glutathione adduction issues, but the ease with which these systems are prepared outweighs the toxicity risks. This article contributes to the need for aniline bioisosteres through the development of a robust, photochemical methodology that supplies 1-aminonorbornanes, saturated bicyclic ring systems that offer similar spatial occupancy to anilines while improving metabolic stability. The chemistry provided herein details an efficient and flexible route toward architecturally distinctive 1-aminonorbornanes through the use of visible-light photoredox catalysis. The incorporation of readily diversifiable functional handles (e.g., -OH, -CO2Me, -NHBoc, -NHCbz) illustrates the potential utility of these 1-aminonorbornanes within drug-discovery programs. Additionally, these motifs offer improved metabolic stability relative to that of their aniline congeners (as demonstrated through microsomal stability assays and metabolite identification efforts), indicating applicability of 1-aminonorbornanes as aniline bioisosteres. This report describes the photochemical conversion of aminocyclopropanes into 1-aminonorbornanes via formal [3 + 2] cycloadditions initiated by homolytic fragmentation of amine radical cation intermediates. Aligning with the modern movement toward sp3-rich motifs in drug discovery, this strategy provides access to a diverse array of substitution patterns on this saturated carbocyclic framework while offering the robust functional-group tolerance (e.g., -OH, -NHBoc) necessary for further derivatization. Evaluating the metabolic stability of selected morpholine-based 1-aminonorbornanes demonstrated a low propensity for oxidative processing and no proclivity toward reactive metabolite formation, suggesting a potential bioisosteric role for 1-aminonorbornanes. Continuous-flow processing allowed for efficient operation on the gram scale, providing promise for translation to industrially relevant scales. This methodology only requires low loadings of a commercially available, visible-light-active photocatalyst and a simple salt; thus, it stays true to sustainability goals while readily delivering saturated building blocks that can reduce metabolic susceptibility within drug development programs.

Macrocyclic MCL-1 inhibitors and methods of use

-

Paragraph 0977, (2019/02/28)

The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

Multicatalytic Stereoselective Synthesis of Highly Substituted Alkenes by Sequential Isomerization/Cross-Coupling Reactions

Romano, Ciro,Mazet, Clément

supporting information, p. 4743 - 4750 (2018/04/10)

Starting from readily available alkenyl methyl ethers, the stereoselective preparation of highly substituted alkenes by two complementary multicatalytic sequential isomerization/cross-coupling sequences is described. Both elementary steps of these sequences are challenging processes when considered independently. A cationic iridium catalyst was identified for the stereoselective isomerization of allyl methyl ethers and was found to be compatible with a nickel catalyst for the subsequent cross-coupling of the in situ generated methyl vinyl ethers with various Grignard reagents. The method is compatible with sensitive functional groups and a multitude of olefinic substitution patterns to deliver products with high control of the newly generated C=C bond. A highly enantioselective variant of this [Ir/Ni] sequence has been established using a chiral iridium precatalyst. A complementary [Pd/Ni] catalytic sequence has been optimized for alkenyl methyl ethers with a remote C=C bond. The final alkenes were isolated with a lower level of stereocontrol. Upon proper choice of the Grignard reagent, we demonstrated that C(sp2) - C(sp2) and C(sp2) - C(sp3) bonds can be constructed with both systems delivering products that would be difficult to access by conventional methods.

Copper-Catalyzed Enantio-, Diastereo-, and Regioselective [2,3]-Rearrangements of Iodonium Ylides

Xu, Bin,Tambar, Uttam K.

supporting information, p. 9868 - 9871 (2017/08/08)

The first highly enantioselective, diastereoselective, and regioselective [2,3]-rearrangement of iodonium ylides has been developed as a general solution to catalytic onium ylide rearrangements. In the presence of a chiral copper catalyst, substituted allylic iodides couple with α-diazoesters to generate metal-coordinated iodonium ylides, which undergo [2,3]-rearrangements with high selectivities (up to >95:5 r.r., up to >95:5 d.r., and up to 97 % ee). The enantioenriched iodoester products can be converted stereospecifically into a variety of onium ylide rearrangement products, as well as compounds that are not accessible by classical onium ylide rearrangements.

DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA

-

Paragraph 00104, (2016/05/24)

Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORy. Also provided are pharmaceutical compositions co

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 130312-00-4